<DOC>
	<DOC>NCT02759250</DOC>
	<brief_summary>To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).</brief_summary>
	<brief_title>A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Inclusion criteria: Age ≥18 years. Written informed consent prior to any studyrelated procedure Willing and able to comply with protocolspecified procedures and scheduled evaluations Pathological diagnosis of nasopharyngeal carcinoma (NPC) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1or 2 Absolute neutrophil count (ANC) &gt; 0.5 x 109/L Haemoglobin &gt; 80 g/L Platelet count ≥ 50 x 109/L Total bilirubin ≤ 2 x the upper limit of normal (ULN) Alanine transaminase (ALT) ≤ 5 x ULN Serum creatinine ≤ 2 x ULN Exclusion criteria: History or clinical evidence of neoplastic central nervous system (CNS) involvement. Note: Irradiated brain metastases that have been stable for &gt; 1 month and do not require systemic glucocorticoid administration are allowed Major surgery within 4 weeks of ARGX110 first dose administration Unresolved grade 3 or 4 toxicity from prior therapy (except mucositis from local radiation therapy). Active, untreated viral, bacterial, or systemic fungal infection Childbearing potential unless using an adequate measure of contraception Pregnancy or lactation. History of hypersensitivity to recombinant proteins Any clinical finding, including psychiatric and behavioural problems, which, in the opinion of the Investigator, precludes the patient from safely participating in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>